Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
Guest Alerts | Access Rights | My Account | Sign In
|
|
Copyright © 2004 by the American Association for the Advancement of Science
Two Sides of a CoinStephen J. Simpson and Eliot Marshall
For autoimmune conditions, immunotherapy offers the potential to limit the damage done by reining in the disease-causing cells. On the opposite side of the balance, clinicians are deploying therapeutic interventions to augment the immune system in its struggle against cancer and chronic viral infections. In this special issue, we've invited experts to review progress in immunotherapy in a range of clinical and experimental settings. Steinman and Mellman (p. 197) set the scene with their view on how basic research in immunology could best be conveyed to the clinical arena, and Blattman and Greenberg (p. 200) explore in detail how this might be achieved to treat malignancy. In many ways, clinicians face similar obstacles in tackling chronic infectious diseases such as HIV, and Autran and colleagues (p. 205) offer insights into the potential of therapeutic vaccines. Transplantation and autoimmunity represent the flip side of the coin, and here the problem is to harness, rather than release, the natural regulatory brakes of the immune system. Waldmann and Cobbold (p. 209) consider how these regulatory processes might be integrated to achieve acceptance of transplanted organs. Finally, Steinman (p. 212) discusses ways in which immunotherapy is being used to target autoimmunue diseases such as multiple sclerosis.
One of the most ambitious clinical projects to date is the U.S. Immune Tolerance Network, which is testing streamlined drug treatments for autoimmune disorders and organ transplantation, described in a News report by Couzin on page 194. On page 170 of the News Focus section, Wickelgren reports on controversial efforts to calm overactive immune systems with a cocktail of parasitic worms. Science Online's STKE and SAGE KE (www.sciencemag.org/sciext/immunotherapy) continue these themes. In STKE, Engleman et al. consider how robust immunity to tumors might be stimulated via dendritic cell activation. Heissmeyer and Rao discuss intracellular pathways regulating T cell tolerance, and Olszewski and Grossbard overview the ways in which a successful mode of antibody immunotherapy achieves its results. In SAGE KE, a Perspective by P. L. McGeer and E. McGeer considers the challenges of vaccination in treating Alzheimer's disease, and a feature story by Leslie explores why vaccines often fail in the elderly--and what scientists are doing to boost their potency. The concepts behind immunotherapy have brought us to an exciting new frontier. The expectations now are that resolution of the diseases discussed in this issue will fall increasingly under our control, rather than appearing to be left to the simple toss of a coin.
The editors suggest the following Related Resources on Science sites:In Science Magazine
In Science Signaling
|
Science Signaling. ISSN 1937-9145 (pre-2008: Science's STKE. ISSN 1525-8882)